Having demonstrated immune-directed impacts of treatment with hCD38-mAtt in a tumor model expressing a human CD38 target, additional in vivo studies were performed using a fully murine surrogate AttenukineTM, namely mCD38-mAtt. The gene discussed is TMEM79; the disease is neoplasm.